An observational study in Knee Osteoarthritis, Gonarthrosis; Primary and Total Knee Arthroplasty, sponsored by Haseki Training and Research Hospital. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-01.
Sponsored by Haseki Training and Research Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 268 studies in Osteoarthritis, Knee with a site in Turkey — 52 open to participants now, 63 under way, 3 of them phase 3. Osteoarthritis, Knee · Turkey.
Among the 268 studies in Osteoarthritis, Knee with a site in Turkey, this one is the 3rd largest by planned enrollment of the 70 observational ones that give a count, is one of 38 that started in 2026, is one of 70 observational ones, reaches primary completion later than 58 of the 62 other live ones, and was the 224th registered.
3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.
Browse Osteoarthritis, Knee studies →52 of the 268 studies in Osteoarthritis, Knee with a site in Turkey are open now. Recruiting first, the newest first:
Bahçeşehir University · Sites in Turkey
Ages 45–65
Munzur University · Sites in Turkey
Ages 55+
Gaziosmanpasa Research and Education Hospital · Sites in Turkey
Ages 45+
Mardin Artuklu University · Sites in Turkey
Ages 40–75
Izmir Democracy University · Sites in Turkey
Ages 30–65 · Women only
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.
This study: 50 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
268 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 38 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 270 is above the median of 100 across 486 observational studies indexed under Osteoarthritis, Knee.
Median enrollment 60 across the 198 interventional studies, 84 across the 70 observational. Of the 183 that completed or were terminated, 3 (2%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 268 have an industry lead sponsor. The 10 most frequent:
Haseki Training and Research Hospital is the lead sponsor of 78 studies on the registry; 17 are open to participants now.
Haseki Training and Research Hospital has 1 study filed under Osteoarthritis, Knee — fewer than ten, so there is no comparison to draw.
26 of the studies in Osteoarthritis, Knee with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07678996Kayseri City HospitalDose-Response Effect of Intra-Articular Ozone in Knee Osteoarthritis | 2026-11-30 |
| NCT06430918Bozyaka Training and Research HospitalNeuropathic Pain and it's Relation to Sleep Quality in Knee Osteoarthritis | 2026-12-01 |
| NCT07883824Kirsehir Ahi Evran UniversitesiAquatic Exercise in Patients With Knee Osteoarthritis | 2026-12-01 |
| NCT07890155Sisli Hamidiye Etfal Training and Research HospitalEffect of Resistance Exercises on Serum IGF-1 Levels in Knee Osteoarthritis | 2026-12-01 |
| NCT07875296Afyonkarahisar Health Sciences UniversityLysyl Oxidase and Lysyl Hydroxylase Levels in Knee Osteoarthritis | 2027-01-03 |
Add all 26 to your calendar (.ics) → With an account.
Among the 268 studies in Osteoarthritis, Knee with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective observational cohort study aims to evaluate the association between perioperative dexamethasone administration and early postoperative recovery following primary total knee arthroplasty. In routine clinical practice, dexamethasone may be administered orally, intravenously, or not administered, depending on the surgeon's established perioperative protocol.
The primary objective is to assess early postoperative recovery in terms of pain intensity, functional mobility, and knee joint range of motion. Secondary objectives include evaluation of inflammatory response, postoperative metabolic changes, opioid requirement, and the severity of postoperative nausea and vomiting (PONV).
Group allocation is non-randomized and determined solely by the standard perioperative management approach routinely applied by the surgeon selected by the patient. No additional interventions are introduced for research purposes. All outcomes are assessed prospectively during the early postoperative period.
Total knee arthroplasty (TKA) is an effective treatment for advanced knee osteoarthritis; however, early postoperative recovery may be influenced by pain severity, limited functional mobility, systemic inflammatory response, metabolic alterations, and postoperative nausea and vomiting. Optimization of perioperative medical management is therefore a key component of enhanced recovery pathways.
Dexamethasone is frequently incorporated into perioperative care due to its anti-inflammatory, analgesic, antiemetic, and metabolic effects. Despite widespread use, variability persists in routine clinical practice regarding route of administration and dosing strategies. Comparative real-world data evaluating oral and intravenous administration within standardized care pathways remain limited.
This study is designed as a single-center, prospective observational cohort investigation evaluating early postoperative recovery parameters associated with routine perioperative dexamethasone strategies. The study does not introduce experimental interventions, randomization, or alterations to established treatment protocols.
Participants are assigned to cohorts according to the routine perioperative management approach of the operating surgeon selected by the patient. Each participating surgeon follows a predefined dexamethasone protocol that was implemented prior to initiation of this study. Treatment allocation is therefore independent of the research process and reflects real-world clinical practice.
The exposure of interest is perioperative dexamethasone administration as part of routine clinical care. Exposure status is defined according to the route of administration applied within the surgeon's established perioperative protocol: intravenous dexamethasone, oral dexamethasone, or no dexamethasone.
The standard institutional regimens consist of 8 mg administered preoperatively and 4 mg administered on postoperative day one, delivered either intravenously or orally depending on routine practice. Patients receiving no dexamethasone serve as the comparison cohort. Exposure classification is determined prior to postoperative outcome assessment.
All surgical procedures are performed using standardized institutional techniques for primary total knee arthroplasty. Postoperative management follows a multimodal analgesic protocol consistent across cohorts. Rescue opioid administration is provided when clinically indicated, and cumulative tramadol dose is recorded. Laboratory monitoring and clinical assessments are performed according to routine perioperative care standards.
Outcome data are collected prospectively using standardized and validated measurement tools during the early postoperative period. Baseline demographic and clinical variables are documented to account for potential confounding factors. Statistical analyses will include appropriate parametric or non-parametric tests depending on distributional assumptions. Repeated measurements will be evaluated using repeated-measures analysis or mixed-effects modeling, with multivariable adjustment to account for baseline differences between cohorts. Statistical significance is defined as p \< 0.05.
The study is conducted in accordance with the Declaration of Helsinki and has received institutional ethics committee approval. All participants provide written informed consent prior to enrollment. Participation does not alter standard clinical management.
The study population consists of adult patients aged 50 to 80 years with a diagnosis of primary knee osteoarthritis who are scheduled to undergo elective primary total knee arthroplasty at Istanbul Sultangazi Haseki Training and Research Hospital. Eligible participants have an ASA physical status of I or II and are able to ambulate independently prior to surgery. All participants are capable of understanding the study procedures and providing written informed consent.
Patients are managed according to the routine perioperative dexamethasone protocols of the surgeon selected by the patient. Group allocation is based on the standard clinical practice of the chosen surgeon and not assigned by the investigators. Participants are followed prospectively to evaluate postoperative pain, inflammatory response, functional mobility, postoperative nausea and vomiting, and analgesic requirements during the early postoperative period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients undergoing primary total knee arthroplasty who receive dexamethasone intravenously according to the routine perioperative protocol of the operating surgeon (8 mg IV preoperatively and 4 mg IV postoperatively).
Other: Routine perioperative management
Patients undergoing primary total knee arthroplasty who receive dexamethasone orally according to the routine perioperative protocol of the operating surgeon (8 mg oral preoperatively and 4 mg oral postoperatively).
Other: Routine perioperative management
Patients undergoing primary total knee arthroplasty who do not receive dexamethasone as part of the routine perioperative management.
Other: Routine perioperative management
This is a prospective observational cohort study. No intervention is assigned by the investigators. Patients are managed according to the routine perioperative dexamethasone protocols of the surgeon chosen by the patient. One cohort receives intravenous dexamethasone (8 mg preoperatively and 4 mg postoperatively), one cohort receives oral dexamethasone (8 mg preoperatively and 4 mg postoperatively), and a control cohort receives no dexamethasone. All other perioperative and postoperative treatments are provided according to standard institutional practice and are not influenced by study participation.
Postoperative Pain Intensity Measured with Visiual Analog Scale (VAS)
Postoperative pain intensity will be assessed using the Visual Analog Scale (VAS), a validated 0 to 10 numeric rating scale, where 0 indicates no pain and 10 indicates the worst imaginable pain. Higher scores represent greater pain intensity and therefore a worse outcome. Pain will be evaluated both at rest and during ambulation.
Time frame: Measuring once in the preoperative period and every 6 hours during the first 48 hours after surgery.
Functional Mobility (Timed Up and Go Test)
Functional mobility will be evaluated using the Timed Up and Go (TUG) test, which measures the time (in seconds) required for a participant to stand up from a seated position, walk three meters, turn, walk back, and sit down. Shorter completion times indicate better functional mobility, whereas longer times indicate poorer performance.
Time frame: Preoperatively and daily during the first 2 postoperative days.
Nausea and Vomiting (PONV) Score
Severity of postoperative nausea and vomiting will be assessed using a 0 to 10 Numeric Rating Scale (NRS), where 0 indicates no symptoms and 10 indicates the most severe nausea or vomiting imaginable. Higher scores represent worse symptoms.
Time frame: Assessed daily during the first 2 postoperative days.
Postoperative Opioid Requirement
Requirement for rescue opioid analgesia following routine postoperative analgesic protocol consisting of scheduled paracetamol (4 doses per day) and NSAIDs (2 doses per day). Total opioid consumption and proportion of patients requiring opioid analgesia will be recorded. Cumulative tramadol dose administered as rescue analgesia will be recorded in milligrams (mg) during the first 48 hours after surgery. Higher values indicate greater postoperative analgesic requirement.
Time frame: During the first 48 hours after surgery.
White Blood Cell Count
Systemic inflammatory response will be assessed by measuring white blood cell (WBC) count, expressed in ×10³/µL. Higher values indicate greater inflammatory response.
Time frame: Preoperatively and daily during the first 2 postoperative days.
C-Reactive Protein Level
ystemic inflammatory response will also be assessed by measuring C-reactive protein (CRP) levels, expressed in mg/L. Higher values indicate greater inflammatory response.
Time frame: Preoperatively and daily during the first 2 postoperative days.
Postoperative Glycemic Response
Serum blood glucose levels will be measured in mg/dL using standard hospital laboratory methods. Daily postoperative values will be recorded to evaluate metabolic response and potential dexamethasone-associated hyperglycemia. Higher values indicate increased glycemic response.
Time frame: Preoperatively and daily during the first 2 postoperative days.
Knee Range of Motion - Flexion and Extension Angles
Knee range of motion will be measured in degrees (°) using a standard universal goniometer aligned with anatomical landmarks (greater trochanter, lateral femoral epicondyle, and lateral malleolus). Measurements will be performed by trained personnel following a standardized protocol to minimize inter-observer variability. Greater flexion angles indicate improved joint mobility, whereas higher extension deficit values indicate reduced extension capacity.
Time frame: Preoperatively and daily during the first 2 postoperative days.
Postoperative Mobilization Status
Postoperative mobilization status will be assessed using a categorical (ordinal) scoring system at postoperative day 0, day 1, and day 2. Patients will be classified into three categories based on their level of mobilization: 0 = Immobilized (no mobilization) 1. = Independently mobilized (without assistance) 2. = Assisted mobilization (with support) This classification is used to describe functional recovery status. Independent mobilization (score 1) represents the best functional outcome, assisted mobilization (score 2) represents moderate recovery, and immobilization (score 0) represents the poorest outcome. All patient groups (intravenous dexamethasone, oral dexamethasone, and control) will be evaluated daily using this scale.
Time frame: Postoperative Day 0, Day 1, and Day 2
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Individual participant data will not be shared due to institutional policies, patient privacy considerations, and the observational nature of this single-center study. The collected data are intended solely for the purposes of this research and related academic publications.
Started Mar 2026 (actual). Primary completion is estimated for Oct 2027, 19 months after the start.
Of 179 non-industry observational studies under Osteoarthritis, Knee, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's planned 19 months is below that.
Counting every sponsor, half of 220 studies reached it within 24 months; a quarter within 13 and three quarters within 61.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Haseki Training and Research Hospital